Phase II study of vincristine, actinomycin-D, cyclophosphamide and irinotecan for patients with newly diagnosed low-risk subset B rhabdomyosarcoma: A study protocol

BACKGROUND: Approximately 80% to 90% of patients with low-risk rhabdomyosarcoma can be cured. However, cured patients often face long-term complications associated with the treatment. An important factor in the treatment plan is the dose of cyclophosphamide administered because the dose can have bot...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Medicine (Baltimore)
Hlavní autoři: Miyachi, Mitsuru, Tsuchiya, Kunihiko, Hosono, Ako, Ogawa, Atsushi, Koh, Katsuyoshi, Kikuta, Atsushi, Hara, Junichi, Teramukai, Satoshi, Hosoi, Hajime
Médium: Artigo
Jazyk:Inglês
Vydáno: Wolters Kluwer Health 2019
Témata:
5700
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6946342/
https://ncbi.nlm.nih.gov/pubmed/31876708
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/MD.0000000000018344
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky